| Enhancing Research Efficiency and Regulatory Compliance with Optimized Digital Data Management
JNPMEDI (CEO, KwunHo Jeong) and Samjin Pharmaceutical Co., Ltd. (CEO, YongJu Choi) signed Master Service Agreement (MSA) at JNPMEDI headquarter on the 11th. Through this agreement, JNPMEDI will develop a tailored intellectual property (IP) strategy for Samjin Pharmaceutical and strengthen legal compliance management, enhancing the efficiency and stability of clinical trials.
To ensure compliance with various domestic and international regulatory requirements and respond flexibly to market changes, Samjin Pharmaceutical has adopted JNPMEDI’s dedicated clinical trial support services. Moving forward, JNPMEDI will establish a dedicated team for Samjin Pharmaceutical to provide comprehensive support, including clinical trial design, data management, regulatory compliance, and market entry strategies. This collaboration aims to optimize clinical operations and maximize research outcomes.
In particular, JNPMEDI will leverage its proprietary Maven Clinical Cloud platform to support Samjin Pharmaceutical in key areas such as clinical data management (DM), statistical analysis (STAT), and pharmacovigilance (PV). Additionally, JNPMEDI will provide regulatory-compliant solutions, including Maven Safety, TMF, and eConsent, to enhance the reliability and efficiency of clinical research.
The pharmaceutical and biotechnology industries are increasingly facing the risk of patent litigation and legal disputes during early IP development and clinical trials. Such conflicts can significantly impact the entire process, while regulatory agencies impose stricter compliance requirements on companies. To proactively address these challenges, JNPMEDI will develop a customized legal strategy for Samjin Pharmaceutical’s clinical projects, minimizing uncertainties in the early development phase. Furthermore, JNPMEDI will establish a compliance framework tailored to regulatory demands and operate a legal risk response hotline for swift action.
SangJin Jeon, Executive Director of Samjin Pharmaceutical, stated, “The success of clinical trials depends not only on research efficiency but also on rigorous legal preparedness. This agreement will enable us to conduct clinical trials that meet regulatory requirements with greater stability.”
KwunHo Jeong, CEO of JNPMEDI, emphasized, “Customized IP strategies and legal risk management are critical components of clinical trials. Through our collaboration with Samjin Pharmaceutical, we will optimize research processes and strengthen market competitiveness.”
With this agreement, JNPMEDI will solidify its role as a strategic partner to Samjin Pharmaceutical, enhancing regulatory compliance and legal stability within the clinical trial environment. By providing tailored solutions, JNPMEDI aims to support the successful execution of clinical research.
| Enhancing Research Efficiency and Regulatory Compliance with Optimized Digital Data Management
JNPMEDI (CEO, KwunHo Jeong) and Samjin Pharmaceutical Co., Ltd. (CEO, YongJu Choi) signed Master Service Agreement (MSA) at JNPMEDI headquarter on the 11th. Through this agreement, JNPMEDI will develop a tailored intellectual property (IP) strategy for Samjin Pharmaceutical and strengthen legal compliance management, enhancing the efficiency and stability of clinical trials.
To ensure compliance with various domestic and international regulatory requirements and respond flexibly to market changes, Samjin Pharmaceutical has adopted JNPMEDI’s dedicated clinical trial support services. Moving forward, JNPMEDI will establish a dedicated team for Samjin Pharmaceutical to provide comprehensive support, including clinical trial design, data management, regulatory compliance, and market entry strategies. This collaboration aims to optimize clinical operations and maximize research outcomes.
In particular, JNPMEDI will leverage its proprietary Maven Clinical Cloud platform to support Samjin Pharmaceutical in key areas such as clinical data management (DM), statistical analysis (STAT), and pharmacovigilance (PV). Additionally, JNPMEDI will provide regulatory-compliant solutions, including Maven Safety, TMF, and eConsent, to enhance the reliability and efficiency of clinical research.
The pharmaceutical and biotechnology industries are increasingly facing the risk of patent litigation and legal disputes during early IP development and clinical trials. Such conflicts can significantly impact the entire process, while regulatory agencies impose stricter compliance requirements on companies. To proactively address these challenges, JNPMEDI will develop a customized legal strategy for Samjin Pharmaceutical’s clinical projects, minimizing uncertainties in the early development phase. Furthermore, JNPMEDI will establish a compliance framework tailored to regulatory demands and operate a legal risk response hotline for swift action.
SangJin Jeon, Executive Director of Samjin Pharmaceutical, stated, “The success of clinical trials depends not only on research efficiency but also on rigorous legal preparedness. This agreement will enable us to conduct clinical trials that meet regulatory requirements with greater stability.”
KwunHo Jeong, CEO of JNPMEDI, emphasized, “Customized IP strategies and legal risk management are critical components of clinical trials. Through our collaboration with Samjin Pharmaceutical, we will optimize research processes and strengthen market competitiveness.”
With this agreement, JNPMEDI will solidify its role as a strategic partner to Samjin Pharmaceutical, enhancing regulatory compliance and legal stability within the clinical trial environment. By providing tailored solutions, JNPMEDI aims to support the successful execution of clinical research.